Propanc Biopharma, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2018, compared with fiscal 2017. Although the request metadata references “2017 Q4,” this is an annual report for fiscal 2018. The filing was signed September 17, 2018. Amounts are in U.S. dollars unless noted.
Business context
Propanc is a pre-revenue development-stage biopharmaceutical company based in Australia. Its lead candidate, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen intended for cancer treatment. At the filing date, PRP remained preclinical; human clinical trials had not begun. The company reported preclinical findings and an FDA Orphan Drug Designation for pancreatic cancer. Its request for orphan designation for ovarian cancer was denied.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $3.960 million | $5.740 million |
| Research and development | $1.826 million | $0.972 million |
| Operating loss | $3.960 million | $5.740 million |
| Net loss | $7.039 million | $7.868 million |
| Interest expense | $2.789 million | $3.203 million |
| Operating cash used | $2.178 million | $2.051 million |
| Financing cash provided | $2.396 million | $2.099 million |
Margins are not meaningful because the company generated no revenue. The smaller net loss year over year reflected lower administration expense and other expense movements; R&D spending increased about 88% as manufacturing and process development advanced. Foreign-currency transaction loss was $0.695 million, versus a $0.145 million gain in FY 2017. The company received an Australian R&D tax credit of $0.179 million, down from $0.306 million.
At June 30, 2018, cash was $19,921, total current assets were $60,890, and total assets were $71,387. Current liabilities were $6.823 million, including $4.699 million of convertible notes and accrued interest, net of discounts and premiums, and $1.522 million of accounts payable and accrued expenses. Working capital deficit was $6.762 million; stockholders’ deficit was $6.752 million; accumulated deficit was $45.283 million. The auditor cited substantial doubt about the company’s ability to continue as a going concern.
FY 2018 financing cash flow included $2.890 million of convertible-note proceeds and $0.490 million of note repayments. Cash declined from $69,043 to $19,921, including a negative $0.268 million foreign-exchange effect. The company said available cash and existing commitments were insufficient to meet obligations for the next 12 months.
Material changes and capital structure
- Common shares issued increased from 4.58 million at June 30, 2017 to 46.43 million at June 30, 2018, largely reflecting conversions of debt and interest. The filing reports 162.04 million shares outstanding on September 17, 2018.
- Many notes carry conversion prices set at a substantial discount to recent trading prices. The company warns that conversions and resales may cause further dilution and pressure the share price. It reported $165.66 million shares reserved for future issuance to satisfy lender requirements at June 30, 2018.
- Common-stock authorization rose to 400 million shares in January 2018. Stockholders approved a further increase to 4 billion shares, which the company intended to file around September 20, 2018.
- The filing states total debt outstanding under financing arrangements was $2.391 million as of September 12, 2018, while the June 30 balance sheet reports $4.699 million of net convertible notes and related accrued interest. These figures have different dates and may reflect different definitions; investors should reconcile them.
Outlook, risks, contingencies and unusual items
- Management said it hoped to submit a UK clinical trial application in the first half of 2019, subject to financing. The filing also describes a planned Phase Ib study and anticipated Phase IIa work, with a stated Phase IIa study cost of approximately $2.5 million. Timelines are conditional and vary across sections of the filing.
- The company’s development plans depend on raising substantial additional capital. It relies on convertible debt it says it cannot currently repay in cash; certain notes include variable-price conversion terms, default interest and penalty provisions.
- Post-year-end disclosures include further debt conversions at low share prices, new convertible notes, and a $20,362 penalty for prepaying a Power Up note. The filing also describes a two-year University of Jaén collaboration beginning September 2018, with payments of about €52,000 in year one and up to €40,000 in year two, plus 2% of net revenues in royalties.
- Manufacturing is outsourced to Amatsigroup. The company anticipates $2.5 million to $5.0 million of payments over three years under the manufacturing agreement; it incurred $0.702 million in FY 2018 under that agreement.
- Management identified material weaknesses in financial reporting controls: no written control procedures, inadequate segregation of duties, no audit committee, and insufficient financial-reporting review and U.S. GAAP expertise. Management said remediation depends on obtaining capital. Disclosure controls were deemed ineffective.
- Other significant risks include clinical and regulatory failure or delay, uncertain UK/EU regulatory implications of Brexit, dependence on key personnel and third parties, patent risks, limited OTCQB trading liquidity and high share-price volatility. The filing reported no material pending litigation.
Most important facts for investors to verify
- Current cash runway, financing commitments, near-term obligations, and whether the company can fund planned manufacturing and clinical work.
- Reconciliation of June 30 convertible-note carrying value, the $2.391 million debt figure reported as of September 12, matured or renegotiated notes, and subsequent financings and conversions.
- Current fully diluted share count, shares reserved for conversions, authorized-share increase status, and potential dilution under variable-price notes.
- Actual regulatory submission and trial milestones, required approvals, trial budget and manufacturing readiness; the filing’s stated schedules are conditional and not fully consistent.
- Progress in remediating material weaknesses, establishing independent board oversight, and improving financial-reporting controls.
- Evidence supporting PRP’s preclinical claims and the status, scope and enforceability of relevant patent applications.